DCF Advisers’s Biohaven BHVN Stock Holding History

DCF Advisers’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93M	Buy	130,000 +6,500	+5%	+$70K	0.34%	49
2026 Q1	$1.04M	Sell	123,500 -28,000	-18%	-$306K	0.28%	57
2025 Q4	$1.71M	Sell	151,500 -20,000	-12%	-$248K	0.46%	53
2025 Q3	$2.57M	Buy	171,500 +115,000	+204%	+$1.67M	0.83%	35
2025 Q2	$797K	Buy	56,500 +6,000	+12%	+$107K	0.37%	59
2025 Q1	$1.21M	Buy	50,500 +14,500	+40%	+$511K	0.58%	48
2024 Q4	$1.34M	Buy	36,000 +5,000	+16%	+$233K	0.65%	46
2024 Q3	$1.55M	Sell	31,000 -20,700	-40%	-$805K	0.62%	38
2024 Q2	$1.79M	Buy	+51,700	New	+$2.04M	0.92%	31

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DCF Advisers's BHVN Position: Q2 2026 in Review

DCF Advisers increased its Biohaven (BHVN) stake by 5.3% in Q2 2026, buying an estimated $70K and bringing the position to 130,000 shares worth $1.93M. The position accounts for 0.34% of the portfolio, ranked #49.

DCF Advisers first reported a position in BHVN in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.57M in Q3 2025. 296 funds tracked by Wall St. Rank hold BHVN as of Q2 2026.

DCF Advisers held 130,000 shares of Biohaven worth $1.93M as of Q2 2026.
DCF Advisers bought 6,500 Biohaven shares in Q2 2026, an estimated $70K.
Biohaven made up 0.34% of DCF Advisers's portfolio in Q2 2026, its #49 holding.
DCF Advisers first reported a position in Biohaven in Q2 2024 and has held it in 9 quarters since.
DCF Advisers's Biohaven position peaked at $2.57M in Q3 2025.
296 funds tracked by Wall St. Rank held Biohaven as of Q2 2026.

Based on DCF Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.